Literature DB >> 8764048

Importance of the Ser-132 phosphorylation site in cell transformation and apoptosis induced by the adenovirus type 5 E1A protein.

S G Whalen1, R C Marcellus, D Barbeau, P E Branton.   

Abstract

The 289-residue (289R) and 243R early region 1A (E1A) proteins of human adenovirus type 5 induce cell transformation in cooperation with either E1B or activated ras. Here we report that Ser-132 in both E1A products is a site of phosphorylation in vivo and is the only site phosphorylated in vitro by purified casein kinase II. Ser-132 is located in conserved region 2 near the primary binding site for the pRB tumor suppressor and, in 289R, just upstream of the conserved region 3 transactivation domain involved in regulation of early viral gene expression. Mutants containing alanine or glycine in place of Ser-132 interacted with pRB-related proteins at somewhat reduced efficiency; however, all Ser-132 mutants transformed primary rat cells in cooperation with E1B as well as or better than the wild type when both major E1A proteins were expressed. Such was not the case with mutants expressing only 289R. In cooperation with E1B, the Asp-132 and Gly-132 mutants yielded reduced numbers of smaller transformed foci. With activated ras, all Ser-132 mutants were significantly defective for transformation and the rare foci produced were small and contained extensive areas populated by low densities of flat cells. In the absence of E1B, all Ser-132 mutants induced p53-independent cell death more readily than virus expressing wild-type 289R. These results suggested that phosphorylation at Ser-132 may enhance the binding of pRB and related proteins and also reduce the toxicity of E1A 289R, thus increasing transforming activity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8764048      PMCID: PMC190495     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  78 in total

1.  Polyomavirus large T mutants affected in retinoblastoma protein binding are defective in immortalization.

Authors:  A Larose; N Dyson; M Sullivan; E Harlow; M Bastin
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

2.  Analysis of phosphorylation sites in the exon 1 region of E1A proteins of human adenovirus type 5.

Authors:  M L Tremblay; D J Dumont; P E Branton
Journal:  Virology       Date:  1989-04       Impact factor: 3.616

3.  Regulating cell growth: casein-kinase-II-dependent phosphorylation of nuclear oncoproteins.

Authors:  D Carroll; N Santoro; D R Marshak
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1988

4.  Mapping of cellular protein-binding sites on the products of early-region 1A of human adenovirus type 5.

Authors:  C Egan; T N Jelsma; J A Howe; S T Bayley; B Ferguson; P E Branton
Journal:  Mol Cell Biol       Date:  1988-09       Impact factor: 4.272

5.  Large T antigens of many polyomaviruses are able to form complexes with the retinoblastoma protein.

Authors:  N Dyson; R Bernards; S H Friend; L R Gooding; J A Hassell; E O Major; J M Pipas; T Vandyke; E Harlow
Journal:  J Virol       Date:  1990-03       Impact factor: 5.103

6.  The E7 protein of human papillomavirus type 16 is phosphorylated by casein kinase II.

Authors:  J M Firzlaff; D A Galloway; R N Eisenman; B Lüscher
Journal:  New Biol       Date:  1989-10

7.  Sequences in E1A proteins of human adenovirus 5 required for cell transformation, repression of a transcriptional enhancer, and induction of proliferating cell nuclear antigen.

Authors:  T N Jelsma; J A Howe; J S Mymryk; C M Evelegh; N F Cunniff; S T Bayley
Journal:  Virology       Date:  1989-07       Impact factor: 3.616

8.  Binding of the Rb1 protein to E1A products is required for adenovirus transformation.

Authors:  C Egan; S T Bayley; P E Branton
Journal:  Oncogene       Date:  1989-03       Impact factor: 9.867

9.  The region of the HPV E7 oncoprotein homologous to adenovirus E1a and Sv40 large T antigen contains separate domains for Rb binding and casein kinase II phosphorylation.

Authors:  M S Barbosa; C Edmonds; C Fisher; J T Schiller; D R Lowy; K H Vousden
Journal:  EMBO J       Date:  1990-01       Impact factor: 11.598

10.  Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product.

Authors:  K Münger; B A Werness; N Dyson; W C Phelps; E Harlow; P M Howley
Journal:  EMBO J       Date:  1989-12-20       Impact factor: 11.598

View more
  7 in total

1.  Comparative sequence analysis of the largest E1A proteins of human and simian adenoviruses.

Authors:  Nikita Avvakumov; Russ Wheeler; Jean Claude D'Halluin; Joe S Mymryk
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

2.  Phosphorylation within the transactivation domain of adenovirus E1A protein by mitogen-activated protein kinase regulates expression of early region 4.

Authors:  S G Whalen; R C Marcellus; A Whalen; N G Ahn; R P Ricciardi; P E Branton
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

3.  CK2 inhibitors increase the sensitivity of HSV-1 to interferon-β.

Authors:  Miles C Smith; Adam M Bayless; Erica T Goddard; David J Davido
Journal:  Antiviral Res       Date:  2011-06-22       Impact factor: 5.970

4.  Transgenic expression in mouse lung reveals distinct biological roles for the adenovirus type 5 E1A 243- and 289-amino-acid proteins.

Authors:  Yongping Yang; Colin McKerlie; Steven H Borenstein; Zhan Lu; Marco Schito; John W Chamberlain; Manuel Buchwald
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

5.  Phosphorylation events during viral infections provide potential therapeutic targets.

Authors:  Julie A Keating; Rob Striker
Journal:  Rev Med Virol       Date:  2011-11-24       Impact factor: 6.989

Review 6.  Regulation of human adenovirus alternative RNA splicing by the adenoviral L4-33K and L4-22K proteins.

Authors:  Roberta Biasiotto; Göran Akusjärvi
Journal:  Int J Mol Sci       Date:  2015-01-28       Impact factor: 5.923

Review 7.  Cancer Treatment Goes Viral: Using Viral Proteins to Induce Tumour-Specific Cell Death.

Authors:  Jasmine Wyatt; Manuel M Müller; Mahvash Tavassoli
Journal:  Cancers (Basel)       Date:  2019-12-07       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.